What is the projected market valuation of the Neglected Tropical Diseases Diagnosis Market by 2035?

The projected market valuation for the Neglected Tropical Diseases Diagnosis Market is expected to reach 15.11 USD Billion by 2035. Read More

What was the market valuation of the Neglected Tropical Diseases Diagnosis Market in 2024?

The overall market valuation was 8.751 USD Billion in 2024. Read More

What is the expected CAGR for the Neglected Tropical Diseases Diagnosis Market during the forecast period 2025 - 2035?

The expected CAGR for the Neglected Tropical Diseases Diagnosis Market during the forecast period 2025 - 2035 is 5.09%. Read More

Which diagnostic method segment is projected to grow the most by 2035?

The Immunological Assays segment, valued at 4.25 USD Billion in 2024, is projected to grow to 7.35 USD Billion by 2035. Read More

What are the key players in the Neglected Tropical Diseases Diagnosis Market?

Key players in the market include Roche, Abbott, Siemens Healthineers, Thermo Fisher Scientific, BD, Cepheid, Hologic, and Bio-Rad Laboratories. Read More

Which disease type segment is expected to see the highest growth by 2035?

The Dengue segment, valued at 4.251 USD Billion in 2024, is expected to grow to 7.51 USD Billion by 2035. Read More

What is the projected growth for the Molecular Diagnostics segment by 2035?

The Molecular Diagnostics segment is projected to grow from 2.0 USD Billion in 2024 to 3.5 USD Billion by 2035. Read More

How does the market for diagnostic laboratories compare to hospitals in 2025?

In 2024, the market for diagnostic laboratories was valued at 2.1 USD Billion, while hospitals were valued at 2.625 USD Billion, indicating a competitive landscape. Read More

What technology segment is anticipated to have the highest valuation by 2035?

The Rapid Test Kits segment, valued at 3.0 USD Billion in 2024, is anticipated to reach 5.0 USD Billion by 2035. Read More

What role do public health organizations play in the Neglected Tropical Diseases Diagnosis Market?

Public health organizations are projected to increase their market share from 2.526 USD Billion in 2024 to 4.61 USD Billion by 2035. Read More

Neglected Tropical Diseases Diagnosis Market

ID: MRFR/HC/32183-HCR

100 Pages

Rahul Gotadki

Last Updated: April 15, 2026

Neglected Tropical Diseases Diagnosis Market Research Report By Diagnostic Method (Serological Testing, Molecular Diagnostics, Microscopy, Immunological Assays), By Disease Type (Lymphatic Filariasis, Schistosomiasis, Leprosy, Chagas Disease, Dengue), By End User (Hospitals, Diagnostic Laboratories, Research Institutions, Public Health Organizations), By Technology (PCR Technology, Rapid Test Kits, Next-Gen Sequencing, Automated Analyzers) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Neglected Tropical Diseases Diagnosis Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Diagnostic Method (USD Billion) | |
  1. 4.1.1 Serological Testing | |
  2. 4.1.2 Molecular Diagnostics | |
  3. 4.1.3 Microscopy | |
  4. 4.1.4 Immunological Assays |
2. 4.2 Healthcare, BY Disease Type (USD Billion) | |
  1. 4.2.1 Lymphatic Filariasis | |
  2. 4.2.2 Schistosomiasis | |
  3. 4.2.3 Leprosy | |
  4. 4.2.4 Chagas Disease | |
  5. 4.2.5 Dengue |
3. 4.3 Healthcare, BY End User (USD Billion) | |
  1. 4.3.1 Hospitals | |
  2. 4.3.2 Diagnostic Laboratories | |
  3. 4.3.3 Research Institutions | |
  4. 4.3.4 Public Health Organizations |
4. 4.4 Healthcare, BY Technology (USD Billion) | |
  1. 4.4.1 PCR Technology | |
  2. 4.4.2 Rapid Test Kits | |
  3. 4.4.3 Next-Gen Sequencing | |
  4. 4.4.4 Automated Analyzers |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Roche (CH) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Abbott (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Siemens Healthineers (DE) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Thermo Fisher Scientific (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 BD (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Cepheid (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Hologic (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Bio-Rad Laboratories (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY DIAGNOSTIC METHOD |
7. 6.4 US MARKET ANALYSIS BY DISEASE TYPE |
8. 6.5 US MARKET ANALYSIS BY END USER |
9. 6.6 US MARKET ANALYSIS BY TECHNOLOGY |
10. 6.7 CANADA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
11. 6.8 CANADA MARKET ANALYSIS BY DISEASE TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY END USER |
13. 6.10 CANADA MARKET ANALYSIS BY TECHNOLOGY |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY DIAGNOSTIC METHOD |
16. 6.13 GERMANY MARKET ANALYSIS BY DISEASE TYPE |
17. 6.14 GERMANY MARKET ANALYSIS BY END USER |
18. 6.15 GERMANY MARKET ANALYSIS BY TECHNOLOGY |
19. 6.16 UK MARKET ANALYSIS BY DIAGNOSTIC METHOD |
20. 6.17 UK MARKET ANALYSIS BY DISEASE TYPE |
21. 6.18 UK MARKET ANALYSIS BY END USER |
22. 6.19 UK MARKET ANALYSIS BY TECHNOLOGY |
23. 6.20 FRANCE MARKET ANALYSIS BY DIAGNOSTIC METHOD |
24. 6.21 FRANCE MARKET ANALYSIS BY DISEASE TYPE |
25. 6.22 FRANCE MARKET ANALYSIS BY END USER |
26. 6.23 FRANCE MARKET ANALYSIS BY TECHNOLOGY |
27. 6.24 RUSSIA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
28. 6.25 RUSSIA MARKET ANALYSIS BY DISEASE TYPE |
29. 6.26 RUSSIA MARKET ANALYSIS BY END USER |
30. 6.27 RUSSIA MARKET ANALYSIS BY TECHNOLOGY |
31. 6.28 ITALY MARKET ANALYSIS BY DIAGNOSTIC METHOD |
32. 6.29 ITALY MARKET ANALYSIS BY DISEASE TYPE |
33. 6.30 ITALY MARKET ANALYSIS BY END USER |
34. 6.31 ITALY MARKET ANALYSIS BY TECHNOLOGY |
35. 6.32 SPAIN MARKET ANALYSIS BY DIAGNOSTIC METHOD |
36. 6.33 SPAIN MARKET ANALYSIS BY DISEASE TYPE |
37. 6.34 SPAIN MARKET ANALYSIS BY END USER |
38. 6.35 SPAIN MARKET ANALYSIS BY TECHNOLOGY |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSTIC METHOD |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USER |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
45. 6.42 CHINA MARKET ANALYSIS BY DISEASE TYPE |
46. 6.43 CHINA MARKET ANALYSIS BY END USER |
47. 6.44 CHINA MARKET ANALYSIS BY TECHNOLOGY |
48. 6.45 INDIA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
49. 6.46 INDIA MARKET ANALYSIS BY DISEASE TYPE |
50. 6.47 INDIA MARKET ANALYSIS BY END USER |
51. 6.48 INDIA MARKET ANALYSIS BY TECHNOLOGY |
52. 6.49 JAPAN MARKET ANALYSIS BY DIAGNOSTIC METHOD |
53. 6.50 JAPAN MARKET ANALYSIS BY DISEASE TYPE |
54. 6.51 JAPAN MARKET ANALYSIS BY END USER |
55. 6.52 JAPAN MARKET ANALYSIS BY TECHNOLOGY |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USER |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY |
60. 6.57 MALAYSIA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
61. 6.58 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY END USER |
63. 6.60 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY |
64. 6.61 THAILAND MARKET ANALYSIS BY DIAGNOSTIC METHOD |
65. 6.62 THAILAND MARKET ANALYSIS BY DISEASE TYPE |
66. 6.63 THAILAND MARKET ANALYSIS BY END USER |
67. 6.64 THAILAND MARKET ANALYSIS BY TECHNOLOGY |
68. 6.65 INDONESIA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
69. 6.66 INDONESIA MARKET ANALYSIS BY DISEASE TYPE |
70. 6.67 INDONESIA MARKET ANALYSIS BY END USER |
71. 6.68 INDONESIA MARKET ANALYSIS BY TECHNOLOGY |
72. 6.69 REST OF APAC MARKET ANALYSIS BY DIAGNOSTIC METHOD |
73. 6.70 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY END USER |
75. 6.72 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY DIAGNOSTIC METHOD |
78. 6.75 BRAZIL MARKET ANALYSIS BY DISEASE TYPE |
79. 6.76 BRAZIL MARKET ANALYSIS BY END USER |
80. 6.77 BRAZIL MARKET ANALYSIS BY TECHNOLOGY |
81. 6.78 MEXICO MARKET ANALYSIS BY DIAGNOSTIC METHOD |
82. 6.79 MEXICO MARKET ANALYSIS BY DISEASE TYPE |
83. 6.80 MEXICO MARKET ANALYSIS BY END USER |
84. 6.81 MEXICO MARKET ANALYSIS BY TECHNOLOGY |
85. 6.82 ARGENTINA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
86. 6.83 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY END USER |
88. 6.85 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSTIC METHOD |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USER |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USER |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY |
102. 6.99 REST OF MEA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
103. 6.100 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY END USER |
105. 6.102 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY DIAGNOSTIC METHOD, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY DIAGNOSTIC METHOD, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY END USER, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Diagnostic Method (USD Billion, 2025-2035)

Serological Testing
Molecular Diagnostics
Microscopy
Immunological Assays

Healthcare By Disease Type (USD Billion, 2025-2035)

Lymphatic Filariasis
Schistosomiasis
Leprosy
Chagas Disease
Dengue

Healthcare By End User (USD Billion, 2025-2035)

Hospitals
Diagnostic Laboratories
Research Institutions
Public Health Organizations

Healthcare By Technology (USD Billion, 2025-2035)

PCR Technology
Rapid Test Kits
Next-Gen Sequencing
Automated Analyzers

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”